Growth Metrics

Palisade Bio (PALI) Receivables - Net (2011 - 2023)

Palisade Bio (PALI) reported Receivables - Net of $300000.0 for Q1 2023, up 408.47% on a QoQ basis from $59000.0 in Q2 2021.

Palisade Bio (PALI) has 12 years of Receivables - Net data on file, last reported at $300000.0 in Q1 2023.

  • Quarterly Receivables - Net changed N/A year-over-year to $300000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $300000.0 (changed N/A YoY) and the FY2020 annual result came in at $59000.0, up 180.1% from the prior year.
  • Receivables - Net rose to $300000.0 in Q1 2023 per PALI's latest filing, from $59000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $300000.0 in Q1 2023 and bottomed at $8779.0 in Q3 2020.
  • The 4-year median for Receivables - Net is $59000.0 (2020), against an average of $88899.5.
  • The widest annual swing landed in 2019, when Receivables - Net slumped 92.84%; it then surged 248.33% in 2021.
  • Tracing PALI's Receivables - Net over 4 years: stood at $21064.0 in 2019, then jumped by 180.1% to $59000.0 in 2020, then changed by 0.0% to $59000.0 in 2021, then jumped by 408.47% to $300000.0 in 2023.
  • Per Business Quant, the three latest PALI Receivables - Net figures stand at $300000.0 (Q1 2023), $59000.0 (Q2 2021), and $25259.0 (Q1 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Palisade Bio 439.25 Mn 309.68 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 300,000.00
Mar 31, 2023 300,000.00
Jun 30, 2021 59,000.00
Jun 30, 2021 59,000.00
Mar 31, 2021 25,259.00
Mar 31, 2021 25,259.00
Dec 31, 2020 59,000.00
Dec 31, 2020 59,000.00
Sep 30, 2020 8,779.00
Sep 30, 2020 8,779.00
Jun 30, 2020 16,938.00
Jun 30, 2020 16,938.00
Mar 31, 2020 19,014.00
Mar 31, 2020 19,014.00
Dec 31, 2019 21,064.00
Dec 31, 2019 21,064.00
Sep 30, 2019 61,154.00
Sep 30, 2019 61,154.00
Jun 30, 2019 169,905.00
Jun 30, 2019 169,905.00
Mar 31, 2019 237,782.00
Mar 31, 2019 237,782.00
Dec 31, 2018 294,057.00
Dec 31, 2018 294,057.00
Sep 30, 2018 161,979.00
Sep 30, 2018 161,979.00
Jun 30, 2018 478,722.00
Jun 30, 2018 478,722.00
Mar 31, 2018 137,372.00
Mar 31, 2018 137,372.00
Dec 31, 2017 312,802.00
Dec 31, 2017 312,802.00
Sep 30, 2017 37,458.00
Sep 30, 2017 37,458.00
Jun 30, 2017 5,345.00
Jun 30, 2017 5,345.00
Mar 31, 2017 14,715.00
Mar 31, 2017 14,715.00
Dec 31, 2016 10,491.00
Dec 31, 2016 10,491.00
Sep 30, 2016 12,685.00
Sep 30, 2016 12,685.00
Jun 30, 2016 5,085.00
Jun 30, 2016 5,085.00
Mar 31, 2016 39,167.00
Mar 31, 2016 39,167.00
Dec 31, 2015 37,316.00
Dec 31, 2015 37,316.00
Sep 30, 2015 19,159.00
Sep 30, 2015 19,159.00
Jun 30, 2015 18,818.00
Jun 30, 2015 18,818.00
Mar 31, 2015 8,173.00
Mar 31, 2015 8,173.00
Dec 31, 2014 225,524.00
Dec 31, 2014 225,524.00
Sep 30, 2014 32,761.00
Sep 30, 2014 32,761.00
Jun 30, 2014 24,468.00
Jun 30, 2014 24,468.00
Mar 31, 2014 11,359.00
Mar 31, 2014 11,359.00
Dec 31, 2013 10,000.00
Dec 31, 2013 10,000.00
Sep 30, 2013 7,500.00
Sep 30, 2013 7,500.00
Jun 30, 2013 56,755.00
Jun 30, 2013 56,755.00
Mar 31, 2013 104,255.00
Mar 31, 2013 104,255.00
Dec 31, 2012 3,333.00
Dec 31, 2012 3,333.00
Sep 30, 2012 833.00
Sep 30, 2012 833.00
Jun 30, 2012 56,930.00
Jun 30, 2012 56,930.00
Mar 31, 2012 234,375.00
Mar 31, 2012 234,375.00
Dec 31, 2011 234,375.00
Dec 31, 2011 234,375.00